Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial

Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial

Abstract Background and Aim A multicenter, open‐label randomized Phase II trial was conducted to determine whether low‐dose gemcitabine plus nab‐paclitaxel (GnP) could improve tolerability and show equivalent efficacy to the standard‐dose GnP for elderly patients with metastatic pancreatic cancer. M...

Full description

Bibliographic Details
Main Authors: Ken Kamata, Hajime Imai, Hisakazu Matsumoto, Yukitaka Yamashita, Takao Kato, Katsuhisa Nishi, Shunsuke Omoto, Kosuke Minaga, Kentaro Yamao, Tomoko Hyodo, Sung‐Woon Im, Akane Hara, Tomoe Yoshikawa, Rei Ishikawa, Ayana Okamoto, Tomohiro Yamazaki, Atsushi Nakai, Kazuomi Ueshima, Yasutaka Chiba, Mamoru Takenaka, Tomohiro Watanabe, Masayuki Kitano, Masatoshi Kudo
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:JGH Open
Subjects:
chemotherapy
elderly
gemcitabine
nab‐paclitaxel
pancreatic cancer
Online Access:https://doi.org/10.1002/jgh3.12966

Internet

https://doi.org/10.1002/jgh3.12966

Similar Items